IndraLab

Statements

YOD1 activates Leukemia, Promyelocytic, Acute. 1 / 1

| 1

reach

"In acute promyelocytic leukemia (APL), YOD1 raises the PML/RARa oncoprotein’s stability; therefore, a selective YOD1 inhibitor named ubiquitin isopeptidase inhibitor I (G5) may offer the chance to treat APL which is resistant to treatment [30]."

37573347

INDRA sources:

Colored badges next to statement headings correspond to evidence counts from knowledge sources, as shown below. Badges to the left of the | separator correspond to curated knowledge base sources, and badges to the right of it correspond to machine reading systems.

IndraLab

Statements

YOD1 activates Leukemia, Promyelocytic, Acute. 1 / 1

INDRA sources:

Databases

Reading